Objectives: The treatment of recurrent prostate cancer after radiotherapy or brachytherapy through radical prostatectomy has been little indicated due to the concern over the procedure's morbidity. We present the experience of our service with postradiotherapy radical prostatectomy. Materials and Methods: Between 1996 and 2002, 9 patients submitted to radiotherapy due to prostate cancer were treated with salvage surgery for locally recurrent disease. All patients had a biopsy of the prostate confirming the tumor recurrence, increase in the PSA levels and staging without evidence of a systemic disease. We have assessed the morbidity and the recurrence-free survival rate after salvage radical prostatectomy. Results: Preradiotherapy PSA varied from 6.2 to 50 ng/mL (mean 17.3) and clinical staging T1, T2 and T3 in 33.3%, 44.4% and 22.2% of the patients respectively. The interval for the biopsy after conforming external beam radiotherapy or brachytherapy varied from 8 to 108 months (median: 36). Four patients received antiandrogenic therapy neoadjuvant to the surgery with a mean of 7 months (1-48) after radiotherapy. From the six patients potent before the surgery, three have presented erectile dysfunction. Urinary incontinence as well as bladder neck sclerosis occurred in two patients (22.2%). Biochemical recurrence occurred in two individuals (22.2%) 12 months after the surgery. Biochemical recurrence-free survival rate was 77.8% with median follow-up time of 30 months (8-102). Conclusion: Salvage radical prostatectomy is a safe and effective alternative for the treatment of locally recurrent prostate cancer after radiotherapy and brachytherapy.
INTRODUCTION
The various forms of treatment for prostate cancer (PCa) include observation, external-beam radiotherapy, brachytherapy, cryotherapy, hormonal therapy and surgery, however, the decision of the ideal therapy should be individualized (1, 2) . Radical prostatectomy (RP) presents a biochemical recurrence rate of 17 to 33% (3, 4) , while brachytherapy and external-beam radiotherapy 25 to 40% (5, 6) . The individuals that present an increase in their PSA level after radiation therapy and that are possible candidates to salvage radical prostatectomy (SRP) should be submitted to a new staging of the disease, since the in-crease can indicate local recurrence, either systemic or both (2) . Prostatic biopsy is positive in 80 to 100% of the cases (2,7), being fundamental the confirmation of the tumor for the therapeutic decision. Salvage procedures such as antiandrogenic therapy, radical prostatectomy and cryotherapy are options for patients with primary treatment failure. SRP has been efficient in the control of the disease in a period of time, with interesting results, reaching 82% diseasefree survival rate in five years (8, 9) . However, SRP has not been getting more acceptance due to technical challenges of the procedure and significant morbidity, occurring urinary incontinence in 23 to 60%, rectal lesion in 15% and ureter lesion in 5% of the patients operated (8, 10) , with post-operative bladder neck sclerosis in up to 30% of the cases (10, 11) .
We have presented the results of SRP for radiotherapy recurring PCa treated in our institution.
MATERIALS AND METHODS
Nine men with mean age of 59 years (50-75), with biopsies confirming locally recurrent prostate cancer after conforming external beam radiotherapy (XRT) or brachytherapy (BT) were submitted to SRP between 1996 and 2002. Patients were considered candidates for salvage surgery when they presented a biopsy confirming the presence of a tumor, increase in the PSA levels and absence of systemic disease, confirmed by bone scintigraphy, thorax radiography, tomography or magnetic resonance of the abdomen or pelvis with digital prostate examination at the physical exam. From the nine irradiated individuals, four received BT, four XRT and one was treated with both. Data regarding perioperative characteristics were assessed such as operative time, transoperatory bleeding, blood transfusion and hospital stay. In the postoperative follow-up, the erectile function was analyzed by the penetration capacity with or without oral medication, urinary incontinence (> 1 pad/day) and bladder neck sclerosis in all individuals.
RESULTS
Mean follow-up was 30 months . Demographic data of the studied group are represented on Table-1 SRP occurred normally, as Table-2 shows. Pathological staging revealed an organ-confined disease in four patients (44%), extra-prostatic extension occurred in five individuals (56%) and invasion of the seminal vesicles in three (33%). From the four patients that had organ-confined disease, three (75%) had biopsy Gleason score ≤ 7. All three patients with compromised seminal vesicle presented biopsy Gleason score 7 or 8, while 60% of the patients with periprostatic extension presented a Gleason score 8. Organ-confined disease occurred in 75% of the patients with pre-radiotherapy PSA ≤ 10 ng/mL, with the compromise of the seminal vesicles occurred in all patients with PSA level above 20 ng/mL before radiotherapy.
From the nine analyzed patients, seven (78%) kept urinary continence, two presented bladder neck sclerosis (22%) two months after the surgery, and erectile dysfunction occurred in half of the patients (Table-3 ). Two individuals presented urinary incontinence after SRP, being one of them, after internal urethrotomy due to bladder neck sclerosis. Both were treated with artificial sphincter AMS 800. On Table- 4, those results are compared to other series. After the SRP, biochemical recurrence occurred in two cases (22%) after a median time of 15 months requiring the introduction of antiandrogenic hormonal therapy.
Seven patients (78%) had the PSA less than 0.4 ng/mL, without any evidence of the disease, from which five (56%) without hormonal therapy. One patient with pre-XRT PSA levels of 50 ng/mL, clinical stage T3c, presented a recurrence in retroperitoneal lymph nodes, being submitted to cytotoxic chemotherapy followed by radiotherapy in the areas of compromised lymph nodes. All patients are alive after a median follow-up time of 30 months (8 to 102 months). 
DISCUSSION
In this series from the nine patients treated with radical prostatectomy for locally recurrent cancer after primary radiotherapy 78% had disease control, 22% urinary incontinence and 50% erectile dysfunction. Five patients (56%) had no adjuvant treatment without evidence of the disease. SRP was performed without transoperative complications, without the need for blood transfusion and presenting a cancer specific survival rate of 100% in the median follow-up time of 8 years (8-102 months).
SRP, even though associated to a larger control of the prostate cancer locally recurrent after radiotherapy, has received limited attention in the urologic field due to technical challenges during surgery and the potential risk of complications such as urinary incontinence, impotency, bladder neck sclerosis and both rectal and ureteral lesions (8, 9) . Urinary incontinence after SRP has been much more frequent than in conventional radical prostatectomy that varies between 5 and 31% (12), representing a limiting factor for salvage surgery, since the urinary incontinence in this study was 22%, similar to other series with a variation of 16 to 45% (9,10,12). The insertion of the artificial sphincter AMS 800 in the cases of persisting urinary incontinence has offered good results in most of the cases (13), this resource was used in two cases resolving urinary leaks.
This study demonstrates an acceptable complication rate making the results similar to a conventional radical prostatectomy. Mean operative time was of 168 minutes and bleeding mean of 433 mL, with mean hospital stay of 4.8 days, similar to other series (9,10). Vaidya & Soloway reported a mean hospital stay of three days (9) . Rectal lesion did not occur in our initial SRP experience, being in agreement with the reports of up to 0.6% during conventional radical prostatectomy (14) . By analyzing the SRP series the rectal lesion may occur between 2 to 15% and ureteral lesion 5% of the cases, respectively (8, 10) .
The risk of bladder neck sclerosis is substantially high after the SRP (2), the rate of 22% of the study is similar to those observed by other authors as Table-4 (8, 10, 11, 15) shows. According to the results obtained in other studies, bladder neck sclerosis after conventional radical prostatectomy caries between 1 to 4% (16, 17) , however, Touma et al. reported an incidence of 17.5% after SRP (12) . Bladder neck sclerosis after radiotherapy can be a problem of difficult solution, sometimes requiring more complex procedures for an adequate correction such as appendicovesicostomy or ileovesicostomy as described by Pisters et al. (18) .
Erectile dysfunction is considered an inevitable consequence of the SRP, even though preservation of cavernous nerves is possible. When it is possible to preserve neurovascular bundles bilaterally, up to 70% of the patients recuperate their sexual function (10, 17) and urinary continence (10) . In this work the erectile function was preserved in half of the patients previously potent before the surgery.
Clinical stage of post-radiotherapy recurrent prostate cancer is a predictive factor for disease free survival rate (2, 12, 15) , even though Rogers et al. (8) have not observed this correlation (8) . In our series, 44% of the cases of the disease were organ-confined and the involvement of seminal vesicles occurred in 33% of the individuals. In similar studies those findings occurred in 39% and 30% of the cases, respectively (15) . Preoperative PSA levels inferior to 10 ng/mL have a strong correlation to organ-confined disease and higher progression-free survival rate. (2, 8, 11, 12) .
Cryotherapy is a viable alternative in the treatment of radioresistant prostate cancer, however, urinary incontinence and bladder neck sclerosis rates are 73% and 44% respectively. Besides, pelvic pain, dysuria, hematuria, bladder neck sclerosis and urethral fistula are other potential complications of cryotherapy (19) . Another discouraging factor is the reduced control of cancer in relation to SRP (2, 12, 19) .
In this study 55.5% of the individuals were recurrence-free. SRP is a viable and safe alternative to the treatment of radioresistant cancer, however the selection of cases with PSA < 15 ng/mL and Gleason score ≤ 7 offer better results without the need of associated androgenic blockage.
EDITORIAL COMMENT
The authors report on excellent results with post-radiotherapy salvage radical prostatectomy in nine patients. Some considerations can be done, regarding the results obtained herein.
First, one remarkable aspect of the study is the young age range of the patients submitted to salvage radical prostatectomies in this series. Of the nine men, five were under 60 years of age at the time of salvage surgery. Considering that the median time from initial treatment to the establishment of therapeutic failure was 36 months, we can conclude that most patients were really young when receiving the initial radiation treatment. May be that the best window for cure was lost then for these men.
A second intriguing finding is the very low complication rate associated to salvage surgery in the published series, which is considerably lower than that of historical series of greater patient volumes. Urinary incontinence, which approaches 60% in historic series, was observed in only 22% in this study. salvage surgery should be offered to Young men with at least 10-year life expectancy and organ-confined disease.
In a setting in which the media easily distorts scientific truth, we have observed growing numbers of non-surgical options for the initial treatment of younger men with clinically localized prostate cancer. In this situation, the favorable results of salvage surgery are welcome. However, we do not know yet whether the results of this Brazilian study (with small numbers, in fact) or the results of the Mayo Clinic are really reproducible by all our urologic surgeons. Probably, our best strategy concerning this subject would be to inform our urologists that, as we see in muscle-invasive bladder cancer, surgery is still the best initial chance of cure for young men with biologically aggressive prostate cancer.
